[CRS_META] declined: crsociety - pdf request

[Tim C.]

This was sent off-list.
-Tim C.


-------- Original Message --------
Subject: off-list: Use of bowman birk inhibitor
Date: Sat, 22 Dec 2007 05:50:46 -0600
From: Tim C.
To: alpater
CC: rw.marcus

Alan,

Rudolph - rw.marcus@ - requests the pdf below.

Thanks,

-Tim C.
cc: Rudolph

> Subject:  RE: [CR] Use of bowman birk inhibitor
> From: "Rudolph Marcus"
> Date: Sat, 22 Dec 2007 11:53:28 +0100
> To: "'The CR Society Main Discussion List'" <cr at lists.calorierestriction.org>
> 
> 
> Hi Alan, may i ask you for this Pdf, thx in advance and have a nice
> Christmas !, Rudolph
> 
> -----Oorspronkelijk bericht-----
> Van: cr-bounces at lists.calorierestriction.org
> [mailto:cr-bounces at lists.calorierestriction.org] Namens Al Pater
> Verzonden: vrijdag 21 december 2007 20:43
> Aan: mjrose; The CR Society Main Discussion List
> Onderwerp: Re: [CR] Use of bowman birk inhibitor
> 
> From: <mjrose>
> 
> 
>> To prevent cancer. Anyone know anything about this soybean derived product
> 
>> and how iy mighyt fit with CR lifestyle.
> 
> 
> The pdf of the below paper is availed.
> 
> 
> Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks 
> SH, Wein AJ, Kennedy AR.
> Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign 
> prostatic hyperplasia.
> Prostate. 2001 Jun 15;48(1):16-28.
> PMID: 11391683
> 
> BACKGROUND: The Bowman-Birk inhibitor is a soybean-derived protease 
> inhibitor that has anti-inflammatory and anticarcinogenic activities. 
> METHODS: A Phase I trial of Bowman-Birk inhibitor concentrate (BBIC) in 19 
> male subjects with benign prostatic hyperplasia (BPH) and lower urinary 
> tract symptoms (LUTS) has been performed. RESULTS: The results of the trial 
> indicated that there was no dose-limiting toxicity of BBIC. There was a 
> statistically significant decrease in serum PSA levels in all BBIC-treated 
> patients. Some BBIC-treated patients exhibited a relatively large reduction 
> in serum PSA levels, ranging up to a 43% reduction. There was also a 
> statistically significant decrease in serum triglyceride levels and a 
> decrease in prostate volume in the treated patients. The scores recorded in 
> response to a urinary symptom questionnaire indicated improved urinary 
> activities in the BBIC-treated patients; however, the control subjects 
> exhibited similar improvements in urinary activities during the course of 
> the trial. CONCLUSIONS: The data obtained in this trial, particularly the 
> data suggesting that BBIC treatment may lead to reduced serum PSA levels and
> 
> reduced prostate volumes, suggest that a Phase II clinical trial of BBIC for
> 
> the therapy of BPH is warranted.
> 
> -- Al Pater, alpater